NASDAQ:INGN Inogen (INGN) Stock Price, News & Analysis $8.38 -0.28 (-3.19%) As of 03:28 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock About Inogen Stock (NASDAQ:INGN) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Inogen alerts:Sign Up Key Stats Today's Range$8.33▼$8.7350-Day Range$5.87▼$8.7952-Week Range$5.70▼$12.91Volume66,621 shsAverage Volume269,645 shsMarket Capitalization$226.70 millionP/E RatioN/ADividend YieldN/APrice Target$11.00Consensus RatingModerate Buy Company Overview Inogen, Inc. (NASDAQ: INGN) is a medical device company specializing in the development, manufacture and marketing of innovative oxygen therapy solutions. The company’s core focus is on portable oxygen concentrators (POCs) designed to support patients with chronic respiratory conditions such as chronic obstructive pulmonary disease (COPD). Inogen’s offerings aim to provide users with mobility and independence by reducing reliance on traditional compressed-gas cylinders and enabling oxygen therapy on the go. Inogen’s flagship product line, including the Inogen One family of portable oxygen concentrators, leverages proprietary flow technology to deliver continuous and pulse-dose oxygen. These devices are engineered to be lightweight, battery-powered and FAA-approved for in-flight use, addressing both clinical efficacy and user convenience. The company also offers supporting accessories such as batteries, chargers and carrying cases to enhance patient experience and ensure uninterrupted oxygen delivery. Founded in 2001 and headquartered in Goleta, California, Inogen has obtained regulatory clearance from the U.S. Food and Drug Administration (FDA) and CE Mark approval for distribution in Europe. The company serves a global customer base through direct-to-consumer sales channels as well as partnerships with home healthcare providers and distributors across North America, Europe and parts of the Asia-Pacific region. Inogen is led by President and Chief Executive Officer Scott Wilkinson, under whose leadership the company has invested in research and development to expand its product portfolio and support emerging digital health initiatives.AI Generated. May Contain Errors. Read More Inogen Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks81st Percentile Overall ScoreINGN MarketRank™: Inogen scored higher than 81% of companies evaluated by MarketBeat, and ranked 194th out of 946 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.3 / 5Analyst RatingModerate Buy Consensus RatingInogen has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on 1 buy rating, 1 hold rating, and no sell ratings.Upside PotentialInogen has a consensus price target of $11.00, representing about 28.5% upside from its current price of $8.56.Amount of Analyst CoverageInogen has received no research coverage in the past 90 days.Read more about Inogen's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Inogen are expected to grow in the coming year, from ($1.73) to ($1.48) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Inogen is -8.08, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Inogen is -8.08, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioInogen has a P/B Ratio of 1.17. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Inogen's valuation and earnings. Short Interest4.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted3.35% of the float of Inogen has been sold short.Short Interest Ratio / Days to CoverInogen has a short interest ratio ("days to cover") of 4.Change versus previous monthShort interest in Inogen has recently decreased by 15.05%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldInogen does not currently pay a dividend.Dividend GrowthInogen does not have a long track record of dividend growth. Sustainability and ESG3.9 / 5Environmental Score-1.12 Percentage of Shares Shorted3.35% of the float of Inogen has been sold short.Short Interest Ratio / Days to CoverInogen has a short interest ratio ("days to cover") of 4.Change versus previous monthShort interest in Inogen has recently decreased by 15.05%, indicating that investor sentiment is improving significantly. News and Social Media2.7 / 5News SentimentN/A News SentimentInogen has a news sentiment score of 0.95. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.73 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 1 news article for Inogen this week, compared to 3 articles on an average week.Search Interest2 people have searched for INGN on MarketBeat in the last 30 days. Company Ownership1.7 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Inogen insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 1.46% of the stock of Inogen is held by insiders.Percentage Held by Institutions89.94% of the stock of Inogen is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Inogen's insider trading history. Receive INGN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Inogen and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. INGN Stock News HeadlinesPositive Signs As Multiple Insiders Buy Inogen StockSeptember 4, 2025 | uk.finance.yahoo.comNeedham Sticks to Its Buy Rating for Inogen (INGN)August 17, 2025 | theglobeandmail.comThe Top 10 AI Stocks You Need to KnowDiscover the 10 Best AI Stocks to Buy Now! The AI revolution is reshaping the investment landscape, and knowing where to place your bets is crucial. Our free report reveals the 10 top AI stocks that should be on your radar right now. Don't miss your chance to get in on these high-potential tech plays.September 23 at 2:00 AM | TradingTips (Ad)Inogen Inc’s Earnings Call Highlights Growth and InnovationAugust 13, 2025 | msn.comInogen Second Quarter 2025 Earnings: Beats ExpectationsAugust 10, 2025 | finance.yahoo.comInogen Announces Second Quarter 2025 Financial ResultsAugust 9, 2025 | finance.yahoo.comInogen, Inc. (INGN) Q2 2025 Earnings Call TranscriptAugust 8, 2025 | seekingalpha.comInogen Inc (INGN) Q2 2025 Earnings Call Highlights: Steady Growth Amidst ChallengesAugust 8, 2025 | gurufocus.comSee More Headlines INGN Stock Analysis - Frequently Asked Questions How have INGN shares performed this year? Inogen's stock was trading at $9.17 at the beginning of 2025. Since then, INGN stock has decreased by 6.7% and is now trading at $8.5590. How were Inogen's earnings last quarter? Inogen, Inc (NASDAQ:INGN) released its quarterly earnings data on Thursday, August, 7th. The medical technology company reported ($0.15) earnings per share for the quarter, topping the consensus estimate of ($0.22) by $0.07. The medical technology company earned $92.28 million during the quarter, compared to the consensus estimate of $90.40 million. Inogen had a negative net margin of 7.58% and a negative trailing twelve-month return on equity of 13.77%. Read the conference call transcript. Who are Inogen's major shareholders? Inogen's top institutional shareholders include Kent Lake PR LLC (3.92%), Acadian Asset Management LLC (3.78%), Ameriprise Financial Inc. (3.26%) and Armistice Capital LLC (2.46%). View institutional ownership trends. How do I buy shares of Inogen? Shares of INGN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Inogen own? Based on aggregate information from My MarketBeat watchlists, some other companies that Inogen investors own include American Water Works (AWK), Waste Connections (WCN), AU Optronics (AUOTY), DiamondRock Hospitality (DRH), The RMR Group (RMR), Voyager Therapeutics (VYGR) and iShares Micro-Cap ETF (IWC). Company Calendar Last Earnings8/07/2025Today9/23/2025Next Earnings (Estimated)11/06/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED INSTRUMENTS Sub-IndustryMedical Equipment Current SymbolNASDAQ:INGN CIK1294133 Webwww.inogen.com Phone(805) 562-0500FaxN/AEmployees1,030Year Founded2001Price Target and Rating Average Price Target for Inogen$11.00 High Price Target$14.00 Low Price Target$7.00 Potential Upside/Downside+31.7%Consensus RatingModerate Buy Rating Score (0-4)2.50 Research Coverage2 Analysts Profitability EPS (Trailing Twelve Months)($1.06) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$35.89 million Net Margins-7.58% Pretax Margin-7.78% Return on Equity-13.77% Return on Assets-8.52% Debt Debt-to-Equity RatioN/A Current Ratio3.03 Quick Ratio2.67 Sales & Book Value Annual Sales$335.70 million Price / Sales0.67 Cash FlowN/A Price / Cash FlowN/A Book Value$7.30 per share Price / Book1.14Miscellaneous Outstanding Shares27,040,000Free Float26,645,000Market Cap$225.78 million OptionableOptionable Beta1.78 Social Links Elon Musk's Next MoveExplore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.Get This Free Report This page (NASDAQ:INGN) was last updated on 9/23/2025 by MarketBeat.com Staff From Our PartnersTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredA New Way to Double Your Retirement Income?Bloomberg reports that a new class of investments is “entering a golden era,” with yields fueling a retail boo...Investors Alley | SponsoredCrypto Gets Official Government Backing—Here's the WinnerTrump Just Signed the GENIUS Act—One Coin is About to Explode We're at the BEGINNING of smart money really ...Crypto 101 Media | SponsoredForget NVDA. Put $1,000 into this stock nowA massive money shift is underway in the AI market. And it's opening up an extraordinary opportunity in a NEW ...Chaikin Analytics | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredTrump's Law S.1582: $21T Dollar Revolution ComingDo you have money in any of these banks? Chase. Bank of America. Citigroup. Wells Fargo. U.S. Bancorp. I...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Inogen, Inc Please log in to your account or sign up in order to add this asset to your watchlist. Share Inogen With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.